BPC-157 & Peptide Therapy in Dubai: A British GP's Honest Guide

What peptides actually are

Peptides are short chains of amino acids — smaller than proteins, larger than single amino acids — that act as signalling molecules in the body. Insulin is a peptide. So is oxytocin. The peptides marketed for recovery, longevity and body composition (BPC-157, TB-500, CJC-1295, Ipamorelin, Tesamorelin, Sermorelin, GHK-Cu) are synthetic analogues of fragments that occur in human biology.

Marketed claims range from accelerated tendon healing to fat loss, gut repair, deeper sleep and 'biological-age reversal'. The reality is more nuanced: a handful of peptides have credible human data for narrow indications, several have animal data only, and many are sold direct-to-consumer with essentially no regulatory oversight.

BPC-157: what the evidence says — and doesn't

BPC-157 (Body Protection Compound-157) is a 15-amino-acid sequence derived from a gastric protein. Almost all published evidence is preclinical — rodent studies showing accelerated tendon, ligament and gut healing. Mechanistically it appears to upregulate growth factors and nitric oxide signalling at the site of injury.

Human data is extremely limited. There are no large randomised controlled trials. Anecdotal reports from athletes and tendinopathy patients are common but uncontrolled. The World Anti-Doping Agency added BPC-157 to its prohibited list in 2022, which tells you how widely it's used in elite sport — not that it's been proven safe or effective.

In the UAE, BPC-157 is not approved by the Ministry of Health and Prevention (MOHAP) as a licensed medicinal product. It's not stocked by mainstream pharmacies. Clinics that offer it are typically sourcing from compounding pharmacies or grey-market suppliers, which introduces real questions about purity, dosing accuracy and sterility.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic version of a peptide fragment of thymosin beta-4, marketed for soft-tissue recovery and inflammation. Like BPC-157, it sits on the WADA prohibited list. Human trials exist for a related molecule in cardiac repair and dry-eye disease — not for the recovery indications it's being sold for.

Same regulatory picture in the UAE: unlicensed, grey-market, no MOHAP approval as a medicinal product.

Growth hormone secretagogues: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin

These peptides stimulate the pituitary to release the patient's own growth hormone, rather than injecting exogenous GH. Tesamorelin has FDA approval for HIV-associated lipodystrophy and has the strongest evidence base. Sermorelin was historically approved for paediatric GH deficiency. CJC-1295 and Ipamorelin are widely used off-label in longevity clinics, with limited but real human pharmacology data.

Risks include water retention, joint pain, raised fasting glucose and HbA1c, carpal tunnel symptoms, and theoretical concerns around stimulating undiagnosed cancers. None of these are reasons to never use peptides — they're reasons to screen patients properly first and monitor IGF-1, fasting glucose and HbA1c on a defined schedule.

Other peptides you'll hear about

GHK-Cu — copper peptide, mostly topical, decent evidence for wound healing and skin. Generally safer profile.

Epitalon — claimed to lengthen telomeres. Human data is sparse and largely from one Russian research group.

PT-141 (bremelanotide) — actually FDA-approved for hypoactive sexual desire disorder in women. Real drug, real side-effect profile.

Melanotan II — sold for tanning. Associated with serious dermatological and cardiovascular adverse events. We do not recommend it.

UAE regulation: the part nobody wants to talk about

MOHAP regulates medicinal products in the UAE. The vast majority of recovery and longevity peptides — BPC-157, TB-500, CJC-1295, Ipamorelin, Epitalon, Melanotan — are not registered medicinal products in the UAE. Importing them for personal use without a prescription can be a customs issue. Clinics dispensing them are operating in a regulatory grey zone unless the specific peptide and supplier are approved.

Tesamorelin, where used for licensed indications, is a different conversation. Sermorelin similarly has a more established status in some markets.

Practically: if a clinic in Dubai or Abu Dhabi is offering you BPC-157 injections without a full medical workup, without baseline bloods, without a documented indication and without follow-up monitoring — that's not longevity medicine. That's product-pushing.

Who should never be on peptide therapy

Anyone with an active cancer or a personal history of hormone-sensitive cancer (breast, prostate, endometrial) — growth hormone secretagogues are off the table without specialist oncology input.

Pregnancy and breastfeeding — full stop.

Uncontrolled diabetes or pre-diabetes without a plan to monitor glucose response.

Untreated obstructive sleep apnoea — GH peptides can worsen it.

Anyone under 25 with no clear medical indication. The longevity bro-science crowd loves stacking peptides in their twenties. Their endocrine systems are still developing. Don't.

What proper peptide assessment looks like

A full GP consultation covering medical history, family history (especially cancers), current medications, sleep, mental health and goals. A physical examination. Baseline bloodwork: full blood count, U&E, LFTs, HbA1c, fasting glucose, fasting insulin, lipids, IGF-1, TSH, vitamin D, B12, ferritin, testosterone and oestradiol where relevant, PSA in men over 40.

A documented clinical indication — tendinopathy, age-related GH decline with symptoms, post-surgical recovery — not just 'I want to feel better'. A discussion of evidence quality and regulatory status. A monitoring plan with repeat bloods at 8–12 weeks and again at 6 months. A clear stop rule if labs move in the wrong direction.

That's the difference between supervised therapy and a wellness-influencer protocol.

The Aafiyah position

We're a British GP-led primary care clinic. We don't sell peptides as a product. For patients asking about peptide therapy, we offer an honest assessment: review your goals, run the right baseline bloods, screen for contraindications, and have a frank conversation about what the evidence supports and what it doesn't.

Where a peptide has a credible evidence base and a legitimate clinical indication, and where regulatory pathways allow, we'll coordinate care with appropriate specialists. Where the request is being driven by marketing rather than medicine, we'll say so. That's what GP supervision is for.